Printer Friendly

Novartis given approval by FDA to market Apligraf for the treatment of venous leg ulcers

Novartis Pharmaceuticals Corp., East Hanover, NJ, has received approval from the U.S. Food and Drug Administration (FDA) to market Apligraf (graftskin) for the treatment of venous leg ulcers. Apligraf is the only living, bilayered skin construct approved for marketing in the U.S. Venous ulcers affect an estimated 600,000 to one million people in the U.S. The efficacy of Apligraf was evaluated in a study involving 14 centers and 240 patients. When applied to ulcers that had lasted more than one year, Apligraf achieved complete wound healing in more than twice as many patients a compression therapy, Novartis reports. The company says Apligraf resulted in more infection that the patients on compression therapy (29.6% vs. 14%). However, the incidence of wound closure was higher in Apligraf-treated patients. Apligraf, which is manufactured in commercial quantities by Organogenesis in Canton, MA, is also being investigated for the treatment of diabetic foot ulcers, pressure sores, dermatological surgery wounds and burns. Contact: Geoffrey Cook - (973) 781-5486
COPYRIGHT 1998 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1998 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Transplant News
Article Type:Article
Geographic Code:1USA
Date:Jun 15, 1998
Words:166
Previous Article:Swiss voters overwhelmingly reject ban on biotechnology research
Next Article:CryoLife says FDA approves parameters for conducting human testing of BioGlue
Topics:


Related Articles
FDA panel recommends approval of Novartis's Apligraf for use in treatment of diabetic foot ulcers.
FDA approves Novartis' Apligraf for treatment of diabetic foot ulcers.
Organogenesis Apligraf approved by HCFA for payment.
ORGANOGENESIS 4TH QUARTER APLIGRAF SALES SURPASS 4000 UNITS.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |